0.000USD0.000Pre-market 07/24, 09:30 (ET)
133.01MMarket Cap
LossP/E TTM
Key Figures
1.710Open
1.730High
467.05KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.59%Turnover Ratio
1.720Prev. Close
1.660Low
527.03KTurnover
--P/E Static
53.23P/B
0.00%Div Yield TTM
-228.63%ROA
6.30052wk High
0.58Volume Ratio
--Net Profit
79.65MShares
-0.4133EPS TTM
0.74Beta
-1207.46%ROE
1.50052wk Low
4.07%Amplitude
--Gross Margin
133.01MMarket Cap
-3.26Reward/Risk
4.16%Risk Rate
Currency: USD Updated: 2026-07-23 Key Insights
Nervgen Pharma Ord Shs's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 191 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is relatively high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.21.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Nervgen Pharma Ord Shs's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Nervgen Pharma Ord Shs Highlights
StrengthsRisks
Nervgen Pharma Ord Shs News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Nervgen Pharma Ord Shs
NGEN
9
Ionis Pharmaceuticals Inc
IONS
26
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Nervgen Pharma Ord Shs Info
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Ticker SymbolNGEN
CompanyNervgen Pharma Ord Shs
CEORogers (Adam H)
Websitehttps://www.nervgen.com/
Shareholders
FAQs
What is the current price of Nervgen Pharma Ord Shs (NGEN)?
The current price of Nervgen Pharma Ord Shs (NGEN) is 1.67.
What is the symbol of Nervgen Pharma Ord Shs?
The ticker symbol of Nervgen Pharma Ord Shs is NGEN.
What is the 52-week high of Nervgen Pharma Ord Shs?
The 52-week high of Nervgen Pharma Ord Shs is 6.30.
What is the 52-week low of Nervgen Pharma Ord Shs?
The 52-week low of Nervgen Pharma Ord Shs is 1.50.
What is the market capitalization of Nervgen Pharma Ord Shs?
The market capitalization of Nervgen Pharma Ord Shs is 133.01M.
Is Nervgen Pharma Ord Shs (NGEN) currently rated as Buy, Hold, or Sell?
According to analysts, Nervgen Pharma Ord Shs (NGEN) has an overall rating of Buy, with a price target of 10.21.
What is the Earnings Per Share (EPS TTM) of Nervgen Pharma Ord Shs (NGEN)?
The Earnings Per Share (EPS TTM) of Nervgen Pharma Ord Shs (NGEN) is -0.44.
